Securing Life Sciences Supply Chains - where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer-focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capabilities run across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. celares GmbH joined the Biosynth Group in July 2023 and became Biosynth GmbH in November 2023. We are recognized as the leaders in PEGylation services including process development, analytical characterization of PEG conjugates and manufacturing of activated PEGs for almost two decades. Recently, we extended our core competences to ‘bioconjugation’ and to ‘polymers for drug delivery’ in a more general sense, while maintaining PEGs and PEGylation as part of our extended services. Most recently, we were inspected by the local authorities and received GMP certificates for the release analytics of drug substances and for the manufacturing of conjugate vaccines. In addition, we have developed novel multimerization technologies that will benefit the developments of our customers and we offer these technologies in reasonable license agreements.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Robert-Roessle-Str. 10, Building D80 - Otto Warburg Building,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.biosynth.com
- Keywords
- Conjugate vaccine development and GMP production, PEGylation of biomolecules, Customized polymers for drug delivery, Polymers for nanoparticle formulation, Manufacturing of hyperbranched polyglycerols, Analytical method development, qualification and validation, Manufacturing of dedicated activated PEGs, Multiplexing technologies for drug development, Development of antibody drug conjugates and similar bioconjugates.
- HQ
- Berlin
- Competitors
- ChemCon GmbH, Minerva Biolabs GmbH, Fitzgerald Industries Intl- Biosynth, Eucodis Bioscience- Biosynth, Aalto Bio Reagents Ltd.-Biosynth, JENOPTIK Medical (ehem. BG Medical Applications GmbH), Biosynth, Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH, INVAC Deutschland GmbH, Vio Biosynth.
Celares - Biosynth Questions
Celares - Biosynth's website is http://www.biosynth.com
Celares - Biosynth's LinkedIn profile is https://de.linkedin.com/company/celares-gmbh
Celares - Biosynth has
5 employees.
View email and phone details for 5
employees at Celares - Biosynth.
Celares - Biosynth's industry is
Biotechnology Research
Celares - Biosynth's top competitors are
Chemcon Gmbh,
Minerva Biolabs Gmbh,
Fitzgerald Industries Intl- Biosynth,
Eucodis Bioscience- Biosynth,
Aalto Bio Reagents Ltd.-Biosynth,
Jenoptik Medical (Ehem. Bg Medical Applications Gmbh),
Biosynth,
Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh,
Invac Deutschland Gmbh,
Vio Biosynth.
Celares - Biosynth's categories are Biotechnology Research
Celares - Biosynth's founding year is 2003
